Pulmonx to Report Third Quarter 2025 Financial Results on October 29, 2025
Rhea-AI Summary
Pulmonx (Nasdaq: LUNG) will report third quarter 2025 financial results after market close on Wednesday, October 29, 2025.
Management will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET the same day. Interested parties must register online to receive dial‑in details and a personal PIN. A live and archived webcast will be available in the Investors section at https://investors.pulmonx.com/.
Positive
- None.
Negative
- None.
REDWOOD CITY, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the third quarter of 2025 after the close of trading on Wednesday, October 29, 2025. Thereafter, company management will host a conference call to discuss the results beginning at 1:30 p.m. PT / 4:30 p.m. ET.
Parties interested in participating by phone should register using this online form. After registering for the webcast, dial-in details will be provided in an auto-generated e-mail containing a link to the conference phone number along with a personal pin. A live and archived webcast of the event will be available on the “Investors” section of the Pulmonx website at https://investors.pulmonx.com/.
About Pulmonx Corporation
Pulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). Pulmonx’s Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System, LungTraX™ Platform, and StratX® Lung Analysis Reports are designed to assess and treat patients with severe emphysema/COPD who despite medical management are still profoundly symptomatic. Pulmonx received FDA pre-market approval to commercialize the Zephyr Valve following its designation as a “breakthrough device.” The Zephyr Valve is commercially available in more than 25 countries, is included in global treatment guidelines and is widely considered a standard of care treatment option for improving breathing, activity and quality of life in patients with severe emphysema. For more information on the Zephyr Valves and the company, please visit www.Pulmonx.com.
Pulmonx®, AeriSeal®, Chartis®, StratX®, and Zephyr® are registered trademarks and LungTraX™ is a trademark of Pulmonx Corporation.
Investor Contact
Jeremy Feffer
LifeSci Advisors
jfeffer@lifesciadvisors.com
FAQ
When will Pulmonx (LUNG) release Q3 2025 results?
What time is the Pulmonx Q3 2025 earnings call (LUNG)?
How can investors join the Pulmonx (LUNG) conference call?
Where can I watch the Pulmonx Q3 2025 webcast (LUNG)?
Will the Pulmonx (LUNG) webcast be archived after the call?
